Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 20 mg - tablet - excipient ingredients: croscarmellose sodium; hypromellose; lactose monohydrate; sodium stearylfumarate; maleic acid - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 5 mg - tablet - excipient ingredients: croscarmellose sodium; hypromellose; sodium stearylfumarate; maleic acid; lactose monohydrate - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; hypromellose; maleic acid; croscarmellose sodium; sodium stearylfumarate - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril maleate 2.5 mg - enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril 5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials.

United States - English - NLM (National Library of Medicine)

med health pharma, llc - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril maleate 2.5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ?35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials.

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril 5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - enalapril maleate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - enalapril maleate - oral tablet - 20mg

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. heart failure enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decreases the incidence of hospitalization for hea